Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Anus Neoplasms

Neoplasms, Squamous Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Intestinal Diseases

Anus Diseases

Rectal Diseases

Anal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Fluorouracil

Mitomycins

Mitomycin

Manganese

Trace Elements

BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.

BMX-001

Jessi E Delaney, RN, BSN

Erin E Rogers, BS

Chi Lin, MD

In this Phase 1/2 study, the investigators will conduct a safety and efficacy study of the combination of BMX-001 with standard radiation therapy (RT) and concurrent 5-fluorouracil (5FU)/mitomycin in newly diagnosed Anal Squamous Cell Carcinoma (ASCC) patients. The primary objectives are: Phase 1 - is to determine the maximum tolerated dose (MTD) of BMX-001 in ASCC patients receiving RT and concurrent 5FU/mitomycin chemotherapy.2. For phase II part: To examine the impact of BMX-001 on the overall acute ≥ grade 3 toxicity rate of the normal tissue including rectum, bladder, and skin in combination with RT and concurrent 5FU/mitomycin in treatment of newly diagnosed ASCC patients

In this Phase 1/2 study, the investigators will conduct a safety and efficacy study of the combination of BMX-001 with standard radiation therapy (RT) and concurrent 5-fluorouracil (5FU)/mitomycin in newly diagnosed Anal Squamous Cell Carcinoma (ASCC) patients. At the time of writing of this protocol amendment, another Phase 1 study using BMX-001 with concurrent chemotherapy and radiation therapy in patient with newly diagnosed high-grade gliomas (BMX-HGG-001) has completed. This clinical trial has demonstrated no adverse effects in subcutaneous dosing up to 28 mg/subject load with half the loading dose (14 mg/subject) given biweekly for 8 weeks in 12 subjects. Three subjects were enrolled and dosed with 42 mg/subject load with half the loading dose given biweekly for 8 weeks. Of these three subjects, there was one dose-limiting toxicity of grade 3 tachycardia and grade 3 hypotension. The DLT in this subject occurred with the loading dose (42 mg sc). The patient was treated with fluids and hospital admitted for observation for 24 hours during which time the hypotension and tachycardia resolved. The cardiac rhythm was a sinus tachycardia and no other cardiac toxicity was observed. The tachycardia was assumed to have resulted from hypotension occurring following the sub-cutaneous injection of BMX-001 (42 mg). After the loading dose of BMX-001 and the described DLT, the subject continued on study and experienced no tachycardia or hypotension following administration of the subsequent 16 maintenance doses (20 mg sc). The sponsor determined that the Recommended Phase 2 Dose (RP2D) of BMX-001 is 28 mg/subject load followed by 14 mg/subject twice a week for up to eight weeks. This is the maximum dose that was tolerated with no adverse effects.

The most common related toxicity seen in the Phase 1 BMX-HGG-001 trial was grade 1 injection site reaction. There is no apparent toxicity to end organ tissues or bone marrow.

The completion of a Phase 1 clinical trial in patients with high-grade glioma undergoing brain radiation therapy plus chemotherapy with temozolomide has established the RP2D for BMX-001. The RP2D by sub-cutaneous injection is 28 mg/subject load followed by a maintenance dose of 14 mg/subject b.i.w. At the RP2D, there have been no BMX-001 dose limiting toxicities observed.

Based on the completion of Phase 1 and establishment of a RP2D for this treatment regimen in patients undergoing radiation therapy and chemotherapy, the clinical trial described in this protocol of patients with newly diagnosed ASCC will proceed to Dose Level 3, after completion of Dose Level 1 and Dose Level 2, enrolling up to 20 subjects with a safety lead-in of 6 subjects. The reason for the safety lead-in is to confirm safety in subjects in this cohort receiving radiation therapy and 5FU/mitomycin.

In order to evaluate the pharmacokinetics (PK) of BMX-001 in combination with current chemoradiation, blood samples will be drawn for analysis in the a minimum of three and up to 6 patients in enrolled in the safety lead-in.

In this trial, the first dose of BMX-001 will be administered subcutaneously from 4 days up to 1 hour prior to the start of radiation treatment.

Blood will be drawn for PK on the following days: Day 1 (before and after loading dose), Day 8, Day 22 and Day 36. Measures will be obtained at approximately the following times: -1 to 0 hour (before loading dose), 30 minutes after the drug is given, 4 hours post-dose, and 24 hours post-dose. This is described in Appendix A. Samples will be analyzed for BMX-001 using validated analytical methods at Dr. Ivan Spasojevic's laboratory at Duke University.

Skin, GI, and GU symptoms will be measured on the day of screening, weekly during RT, 1 months, 4 months and 10 months after the completion of RT. Perianal skin will be assessed weekly during RT, 1 month, 4 months, and 10 months after completion of RT. Further follow up will be per standard of care.

Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer

A Phase 1 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001

To evaluate patient-reported outcomes (EORTC QLQ C30 and CR29)

To measure 4-hydroxynonenal (4-HNE) in the urine.

To measure 4-hydroxynonenal (4-HNE) in the plasma.

To measure malondialdehyde (MDA) in the urine.

To measure malondialdehyde (MDA) in the plasma.

To measure serum drug concentration of BMX-001 after single-dose and repeated-dose BMX-001 delivery.

MTD is defined as the highest dose level at which ≤ 1 out of 6 experienced DLT.

To examine acute grade 3 of normal tissue per CTCAE 4.0

To examine acute grade 3 rectal bleeding per CTCAE 4.0

To examine acute grade 3 rectal pain per CTCAE 4.0

To examine acute grade 3 diarrhea per CTCAE 4.0

To examine acute grade 3 dysuria per CTCAE 4.0

To examine acute grade 3 hematuria per CTCAE 4.0

To examine acute grade 3 urinary frequency per CTCAE 4.0

To evaluate rate of acute perianal grade 3 radiation dermatitis per CTCAE 4.0

To examine grade 3 late rectal bleeding per CTCAE 4.0

To examine grade 3 rectal fibrosis by endoscopy

To assess local recurrence rate survival (PFS).

To assess locoreginal progression free survival rate survival (PFS).

Spots Global Cancer Trial Database for anal cancer, squamous cell carcinoma